Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)

Kenneth Blum^1-10*, Edward Modestino, J.^7,11, Marjorie Gondre Lewis, C.^7,12, David Baron^1,7, Bruce Steinberg^7,11, Panayotis Thanos, K.^7,13, William Downs, B.¹⁰, David Siwicki^6,7, Lisa Lott⁷, Eric Braverman, R.⁴, Mark Moran⁷, David Miller⁸, Lyle Fried⁷ & Rajendra Badgaiyan, D.^7,14

¹Western University Health Sciences, Graduate School of Biomedical Sciences, Pomona, CA
²Eotvos Loránd University, Institute of Psychology, Budapest, Hungary
³Department of Psychiatry, Wright State University Boonshoft School of Medicine and Dayton VA Medical Center, Dayton, OH, USA
⁴Department of Clinical Neurology, Path Foundation NY, New York, USA
⁵Department of Psychiatry, University of Vermont, Burlington, VM, USA
⁶Dominion Diagnostics, LLC., North Kingston, RI, USA
⁷Division of Precision Addiction Management, Geneus Health, LLC., San Antonio, TX, USA
⁸Division of Addiction Therapy Research, Nupathways, Inc., Meadow Ridge Dr. Innsbrook, MO, USA
⁹Division of Neurogenetic Research & Addiction Therapy, The Florida House Experience, Deerfield Beach, FL, USA
¹⁰Division of Nutrigenomics, Victory Nutrition International. LLC., Lederach, PA
¹¹Department of Psychology, Curry College, Milton, MA, USA
¹²Departments of Anatomy & Psychiatry & Behavioral Sciences, Howard University School of Medicine, Washington, DC, USA
¹³Behavioral Neuropharmacology & Neuroimaging Laboratory on Addiction, Research Institute on Addictions, University of Buffalo, Buffalo, NY, USA
¹⁴Department of Psychiatry, Ichan School of Medicine at Mount Sinai, New York, NY, USA

Dr. Kenneth Blum, Western University Health Sciences, Graduate School of Biomedical Sciences, Pomona, CA, USA.

Keywords: Annotated; Kb220; Restoregen Variant; Genetic Addiction Risk Score (GARS®); Precision Addiction Management (PAM®)

Abstract

Background
We are facing a significant challenge in combatting the current opioid and drug epidemic worldwide. In the USA, although there has been notable progress, in 2017 alone 72,000 people died from a narcotic overdose. The NIAAA & NIDA continue to struggle with innovation to curb or eliminate this unwanted epidemic. The current FDA list of approved Medication Assistance Treatments (MATS) work by primarily blocking dopamine function and release at the pre-neuron in the nucleus accumbens. We oppose this option in the long term tertiary treatment but agree for short term harm reduction potential.
Bibliography Presentation
As an alternative motif, the utilization of a well-researched neuro-nutrient called KB220 has been intensely investigated in at least 38 studies showing evident effects related to everything from AMA rate, attenuation of craving behavior, reward system activation including BOLD dopamine signaling, relapse prevention, as well as reduction in stress, anger, and aggressive behaviors. We are continuing research especially as it relates to genetic risk, including the now patented Genetic Addiction Risk Score (GARS®) and the development of “Precision Addiction Management (PAM)” to potentially combat the opioid/psychostimulant epidemic.
Conclusion
Based on animal research and clinical trials as presented herein, the Pro-Dopamine Regulator known as KB220 shows promise in the addiction and pain space. Other neurobiological and genetic studies are required to help understand the mechanism of action of this neuro-nutrient. However, the evidence to date points to induction of “dopamine homeostasis” enabling an asymptotic approach for epigenetic induced “normalization” of brain neurotransmitter signaling and associated improved function in the face of either genetic or epigenetic impairment of the Brain Reward Cascade (BRC).

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).